Background: Detailed epidemiology for patients with advanced metastatic melanoma in Canada is not well characterized. We conducted an analysis of patients with this disease in the province of Ontario, with the aim being to study the presentation, disease characteristics and course, and treatment patterns for malignant melanoma.
Methods: In this Canadian observational prospective and retrospective study of patients with malignant melanoma, we used data collected in the Canadian Melanoma Research Network (cmrn) Patient Registry. We identified patients who were seen at 1 of 3 cancer treatment centres between April 2011 and 30 April 2013. Patient data from 2011 and 2012 were collected retrospectively using chart records and existing registry data. Starting January 2013, data were collected prospectively. Variables investigated included age, sex, initial stage, histology, mutation type, time to recurrence, sites of metastases, resectability, and previous therapies.
Results: A cohort of 810 patients with melanoma was identified from the cmrn registry. Mean age was 58.7 years, and most patients were men (60% vs. 40%). Factors affecting survival included unresectable or metastatic melanoma, initial stage at diagnosis, presence of brain metastasis, and mutation status. The proportion of surviving patients decreased with higher initial disease stages.
Conclusions: Using registry data, we were able to determine the detailed epidemiology of patients with melanoma in the Canadian province of Ontario, validating the comprehensive and detailed information that can be obtained from registry data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176382 | PMC |
http://dx.doi.org/10.3747/co.23.3161 | DOI Listing |
Doc Ophthalmol
March 2025
Department of Ophthalmology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Purpose: To report our flicker electroretinographic (ERG) findings in a patient who developed uveitis after treatment with immune checkpoint inhibitors (ICIs) for a metastatic malignant melanoma.
Methods: ERGs were used to monitor retinal physiology in a patient with ocular complications following systemic ICI administration. Flicker ERGs were recorded using the RETeval system before and after the ICI treatments.
JAMA Dermatol
March 2025
Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Am J Surg Pathol
March 2025
Department of Dermatology, Feinberg School of Medicine.
Pediatric Spitz melanoma (SM) with bonafide metastatic disease is rare. In this study, we assembled the largest cohort to date of pediatric SM with a verified Spitz-associated genomic driver and clinical follow-up demonstrating bonafide metastasis. We compared the clinical, morphologic, and molecular features of these SMs to a control cohort of 57 pediatric atypical Spitz tumors (ASTs).
View Article and Find Full Text PDFCancer Cell
March 2025
Washington University in St. Louis, Saint Louis, MO, USA. Electronic address:
Melanoma brain metastasis (MBM) is associated with poor prognosis. In this issue of Cancer Cell, Rodriguez-Baena et al. identify nuclear factor κB (NF-κB) (Rela) as a driver of pro-tumoral microglia in MBM.
View Article and Find Full Text PDFRev Esp Enferm Dig
March 2025
Aparato Digestivo, Complejo Asistencial Universitario de Salamanca.
The patient is a 57-year-old woman with a history of Hodgkin's lymphoma in remission. A routine analysis found hepatic profile alterations, and a full liver function test showed SOLs in a non-cirrhotic liver. An anatomopathological study revealed metastatic melanoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!